Orrick Advises Dompé on 2022 R&D Collaboration with and Series A Investment in Engitix


We advised Dompé farmaceutici S.P.A (Dompé) on its multi-year, multi-program strategic research and development collaboration with Engitix Ltd., a biopharmaceutical company with its proprietary human extracellular matrix (ECM) drug target discovery platform, to support the identification of new treatments against fibrosis and liver-associated solid tumors. Dompé will provide access to its Exscalate AI drug discovery platform and drug discovery facilities, in exchange for milestones (including additional equity) and royalties. In connection with the research and development collaboration, we also advised Dompé on its investment in the $54 million Series A financing of Engitix, which was co-led by Dompé and Netherton Investments.

The Orrick team advising Dompé included David Schulman (Washington, DC), Shawn Atkinson (London) and Daniel Kadin (Los Angeles).